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Background: Gastrointestinal (GI) disturbances such as diarrhea and flatulence are the most frequent adverse
effects associated with miglustat therapy in type 1 Gaucher disease (GD1) and Niemann-Pick disease type C (NP-C),
and the most common recorded reason for stopping treatment during clinical trials and in clinical practice settings.
Miglustat-related GI disturbances are thought to arise from the inhibition of intestinal disaccharidases, mainly
sucrase isomaltase. We report the effects of a co-administered dietary probiotic, S. boulardii, on the GI tolerability of
miglustat in healthy adult subjects.
Methods: In a double-blind, placebo-controlled, two-period, two-treatment cross-over trial, healthy adult male
and female subjects were randomly allocated to treatment sequences, A–B and B–A (treatment A - miglustat
100 mg t.i.d. + placebo; treatment B - miglustat 100 mg t.i.d. + S. boulardii [500 mg, b.i.d.]). GI tolerability
data were collected in patient diaries. The primary endpoint was the total number of ‘diarrhea days’ (≥3 loose stools
within a 24-h period meeting Bristol Stool Scores [BSS] 6–7) based on WHO criteria. Secondary endpoints comprised
numerous other diarrhea and GI tolerability indices.
Results: Twenty-one subjects received randomized therapy in each treatment sequence (total N = 42), and overall,
37 (88 %) subjects completed the study. The total number of diarrhea days was <1.5 for both treatment sequences,
and approximately 60 % of subjects did not experience diarrhea during either treatment period. The mean (SD)
number of diarrhea days was lower with miglustat + S. boulardii (0.8 [2.4] days) than with miglustat + placebo
(1.3 [2.4] days), but the paired treatment difference was not statistically significant (−0.5 [2.4] days; p = 0.159).
However, a significant treatment difference (−0.7 [1.9]; p < 0.05) was identified after post hoc exclusion of a clear
outlier who had a very high number of diarrhea days (n = 13) and inconsistent GI tolerability reporting. The incidence
of the GI AEs was higher with miglustat + placebo (82 %) than with miglustat + S. boulardii (73 %). There were no
between-treatment differences in miglustat pharmacokinetics.
Conclusions: Although the primary endpoint was not met, the results of the post-hoc analysis suggest that
co-administration of miglustat with S. boulardii might improve GI tolerability.
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The reversible glucosylceramide synthase inhibitor, miglu-
stat (Zavesca®; Actelion Pharmaceuticals Ltd, Switzerland),
is approved in the EU, the US, and other countries for the
treatment of adult patients with mild or moderate type 1
Gaucher disease (GD1) for whom enzyme replacement
therapy (ERT) is either unsuitable or not a therapeutic
option [1, 2]. Miglustat is also indicated for the treatment
of progressive neurological manifestations in adult and
pediatric patients with Niemann-Pick type C disease
(NP-C) in the EU, Japan, and other countries [2].
Safety and tolerability monitoring during clinical trials
in both GD1 [3–6] and NP-C [7–10] has consistently
shown gastrointestinal (GI) disturbances such as diar-
rhea, flatulence, abdominal discomfort, nausea and
vomiting as the most frequent adverse effects associated
with miglustat therapy. These GI adverse effects oc-
curred primarily during the first 6 months of treatment,
and were observed in 80 % of patients during the first
6 months compared with 50–60 % thereafter [2], and
have been reported as the most common reason for
miglustat discontinuation [11, 12]. GI tolerability is
therefore an important matter as it can have an impact
on treatment compliance (particularly among young pa-
tients with NP-C), thereby reducing treatment benefits.
GI disturbances during miglustat treatment are
thought to arise from the inhibition of intestinal disac-
charidases, mainly sucrase isomaltase [11, 13–15].
Miglustat (1,5 (butylimino)-1,5-dideoxy-D-glucitol) – a
glucose analog – inhibits the human disaccharidase, su-
crase, which cleaves sucrose at the O-C (glucose) bond
[14, 16, 17]. Furthermore, relatively little inhibition of
intestinal lactase, and down-regulation of sucrase ex-
pression in gastrointestinal epithelium have been ob-
served [11, 13–15]. Together, these effects lead to
maldigestion of sucrose [11], preventing the release
of the monosaccharides, glucose and fructose, for
further intestinal absorption. Undigested sucrose that
is not absorbed subsequently causes osmotic diarrhea
[11, 18]. Bacterial fermentation of unabsorbed mater-
ial can also lead to flatulence and abdominal distension/
discomfort [18].
Adaptations within the GI system, such as an en-
hanced capacity for fermentation in the cecum via adap-
tation of the microflora, are considered to account for
partial resolution of GI disturbances in miglustat-treated
patients over time. Additionally, anti-propulsive medica-
tions (e.g., loperamide) can help to ameliorate GI
disturbances such as diarrhea [3, 18–22]. Dietary mod-
ifications at or before initiation of miglustat therapy
(e.g., adoption of a low-carbohydrate diet, alongside
changes to maintain adequate caloric intake) have also
been shown to have some positive impact on GI toler-
ability [11, 23], and a gradual increase in dose up to the fulldose during the first 3 weeks of therapy has been found to
be helpful (Amato D, personal communication).
Other methods to improve the GI tolerability of miglustat
have been suggested, but as yet there are few published data
to support their use. The probiotic delivery of additional su-
crase activity to the lower intestine during either initial or
ongoing miglustat therapy has been suggested as a way to
enhance GI adaptation. A purified formulation of the
saccharomyces cerevisiae-derived invertase, sacrosidase
(Sucraid®), was shown to be beneficial in patients with con-
genital sucrase-isomaltase deficiency – a condition where
patients experience GI symptoms that are analogous to
those observed in miglustat-treated patients [24, 25] – and
was also successful in alleviating diarrhea in a pediatric NP-
C patient (Marquardt T, personal communication). Admin-
istration of lyophilized S. cerevisiae (Baker‘s yeast) has also
been reported to improve clinical symptoms in children with
congenital sucrase-isomaltase deficiency [26]. A Phase 1 clin-
ical study with miglustat showed a positive effect on
treatment-related diarrhea after co-administration with
Baker‘s yeast extract (Saccharomyces cerevisiae; data on file
at Actelion).
There is anecdotal evidence of favorable effects from
the co-administration of miglustat with Saccharomyces
boulardii probiotics (Burlina A, personal communica-
tion). S. boulardii produces a high amount of invertase
[27, 28], and may be a good candidate because yeast-
secreted sucrase cleaves sucrose at the O-C (fructose)
bond [17] and is not expected to be inhibited by miglu-
stat, which is a glucose analog. The probiotic formula-
tion, Florastor® (syn. HANSEN CBS5926; Biocodex,
France) contains lyophilized cells of the S. boulardii
CNCM I-745 yeast strain, and is indicated in both adults
and children for the reduction of diarrhea from a
number of causes (e.g., recurrent Clostridium difficile-
associated diarrhea, GI relapses of Crohn’s disease or ul-
cerative colitis). We report findings from a clinical study
that assessed the effect of this widely available probiotic
formulation on the GI tolerability profile of miglustat in
healthy subjects.
Methods
Study design and subjects
This was a randomized, double-blind, placebo-controlled,
two-period, two-treatment cross-over Phase 1 trial con-
ducted at the Phase 1 unit at BioPharma Services Inc
(Toronto, Canada) in healthy adult subjects between
25 February and 7 June, 2013. The primary objective
was to assess whether co-administration of S. boulardii de-
creases the total number of days of diarrhea in healthy sub-
jects receiving miglustat. The safety of co-administration of
S. boulardii with miglustat, and any effect of S. boulardii
co-administration on miglustat steady-state pharmacokin-
etics (PK) were also evaluated.
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treatment cross-over period, and a serious adverse
event (SAE) follow-up period. Healthy subjects were
enrolled and randomly allocated to two different
treatment sequences, A-B and B-A, where treatment
A was miglustat + placebo and treatment B was
miglustat + S. boulardii. Treatment allocation was based
on a computer-generated, randomization schedule pre-
pared by Clinipace Worldwide. Each treatment period
consisted of 14 days of miglustat treatment, with initi-
ation of S. boulardii/placebo 2 days before miglustat. The
two treatment periods were separated by a 10- to 14-day
treatment-free washout (Fig. 1).
Ethical considerations
The study protocol and all associated materials were
reviewed and approved by an independent ethics com-
mittee and the study was conducted in full compliance
with the Declaration of Helsinki, International Committee
on Harmonization guidelines for Good Clinical Practice
(GCP), and the US Code of Federal Regulations. All sub-
jects provided written informed consent in line with GCP
and local requirements before participation.
Subjects and treatment
Healthy male and female subjects aged 18–55 years, and
with a BMI of 18.5–30.0 kg/m2 were included. Women
were required not to be lactating or pregnant, and both
men and women were required to be using reliable
contraception. Study subjects were required not to have
any clinically significant findings on the physical examin-
ation, laboratory assessment, electrocardiogram (ECG)
and vital signs at screening.
Subjects with a known history of yeast allergy, un-
planned weight loss of ≥5 % body weight within 1 month
or ≥10 % within 6 months of study start, and those who
received anti-diarrheal medications (e.g., loperamide),
oral probiotic supplements or S. boulardii within 30 days,Fig. 1 Study design. Subjects received S. boulardii or placebo alone (i.e., wior anti-fungal medications or antibiotics within 8 weeks
of study start were excluded from the study. Subjects on
any specialized diet were also excluded, as were those
with a history of lactose intolerance, irritable bowel syn-
drome, inflammatory bowel disease (IBD), or other dis-
eases resulting in frequent or severe diarrhea, or a
history of GI distress including diarrhea (more than two
loose stools per day for ≥5 days) within 30 days of study
start.
Doses of miglustat and S. boulardii were based on
manufacturers’ instructions (Florastor® Biocodex). Miglustat
was administered at a dose of 300 mg/day (100 mg t.i.d.)
at consistent regular intervals during the day, at least
1 h prior to or after meals (e.g., morning, afternoon,
and evening) [2]. S. boulardii was taken at doses of
1000 mg/day (500 mg, b.i.d.) with the morning and
evening miglustat dose. S. boulardii placebo capsules
contained only excipients, and were identical in ap-
pearance to active S. boulardii capsules; both were
provided by Biocodex (France).
Compliance with study treatment was monitored
based on pill count at each study visit. Subjects had to
discontinue if they took <80 % of supplied study medica-
tion as per medication reconciliation at the end of each
study visit.
Probiotics, other investigational drugs, and any other
over-the-counter medications (including homeopathic
preparations, herbal medicines, vitamins and minerals)
were not allowed during the study. Anti-diarrheal medi-
cations were also not allowed unless directed by the
principal investigator due to an adverse event.
Assessments
GI tolerability data were derived from information col-
lated from diaries that subjects filled out daily during
3 days before study drug initiation and on each day dur-
ing the study treatment periods (i,e., Days 1–16 and
Days 29–44). Items addressed in the diaries comprisedthout miglustat) during the first 2 days of each period
Table 1 Baseline characteristics (all-randomized set)







(n = 21) (n = 21) (N = 42)
Age, mean (SD) 39.6 (8.9) 35.8 (10.8) 37.7 (10.0)
Gender, n (%)
male
11 (52) 8 (38) 19 (45)
Race, n (%):
Caucasian 12 (57) 8 (38) 20 (48)
Black 4 (19) 11 (52) 15 (36)
Asian 5 (24) 2 (10) 7 (17)
Mean weight, kg 72.7 71.7 72.2
BMI, mean (SD)
kg/m2
25.5 (2.9) 25.4 (3.5) 25.4 (3.2)
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stools and the presence/absence of several categories of
GI distress. Diarrhea was assessed based on WHO cri-
teria [29], the Bristol Stool Score (BSS; a seven-point
scale rating stools from 1 [hard stools] to 7 [entirely
liquid]) [30] and the Patient-Reported Outcomes version
of the Common Terminology Criteria for Adverse
Events (PRO-CTCAE).
The primary study endpoint was the total number of
‘diarrhea days’, with one ‘diarrhea day’ defined as ≥3
loose stools within a 24-h period (WHO criteria) that
matched BSS diarrhea criteria of 6–7 (based on subject
diary information). Secondary endpoints included the
number of ‘consecutive diarrhea days’, the frequency and
maximum severity of reported GI events (diarrhea,
nausea, bloating, belching, flatulence, indigestion/upset
stomach, and/or abdominal pain rated on a 5-point scale
ranging from 0 [none] to 4 [very severe] inclusive), the
mean daily interference score for subjects with GI events
(an indication of the extent to which GI symptoms inter-
fered with subjects’ daily activities based on a 5-point
scale graded from 0 [not at all] to 4 [very much]), mean
daily BSS, the frequency of premature treatment discon-
tinuations related to GI AEs, and the proportion of sub-
jects unable to maintain their usual diet.
Pharmacokinetics
Miglustat plasma concentrations were measured by
Swiss BioAnalytics AG (Switzerland) according to a vali-
dated liquid chromatography-tandem mass spectrometry
(LC-MS/MS) assay using blood samples taken on the
last day of each study treatment period, just before the
next miglustat dose (i.e., Days 16 and 46). Miglustat peak
concentration (Cmax) and Tmax were obtained directly
from miglustat concentration–time profiles. The area
under the concentration–time curve at defined time ‘τ’
(AUCτ) was calculated according to the linear trapez-
oidal rule.
Safety and tolerability
Safety and tolerability were evaluated based on adverse
events (AEs), serious adverse events (SAEs), physical
examinations, vital signs, routine hematological, bio-
chemical and urinalysis laboratory assessments, and
body weight.
Data analysis
All randomized subjects in this study took their first
dose of study medication. The ‘all randomized’ set was
therefore equivalent to the ‘all-treated’ set, and was used
to evaluate subject disposition, baseline characteristics,
previous and concomitant therapies, treatment exposure,
and safety endpoints. The per-protocol (PP) set com-
prised all subjects from the all-treated set who hadcompleted both treatment Periods 1 and 2 without any
major protocol violations. The PP set was used for ana-
lysis of the primary endpoint, as well as secondary GI
tolerability endpoints. No data imputation was applied
to missing study data.
A sample size of 34 subjects was required to provide
80 % power to detect a paired mean difference of 4.0
diarrhea days with an estimated SD of 8.0 diarrhea
days at the two-sided significance level of α = 0.05.
An assumed 20 % dropout increased the total sample size
to 42 subjects. The null hypothesis of no difference be-
tween the miglustat + S. boulardii and miglustat + placebo
treatments was tested against the two-sided alternative
hypothesis that it was not equal to zero. The paramet-
ric paired t-test was used for hypothesis testing if the
assumption of normal distribution was met. If not, then
the non-parametric Wilcoxon paired signed rank test
was used. In addition, post hoc sensitivity analyses of
the primary endpoint based on the PP set were conducted
that excluded an outlier subject, and other continuous GI
endpoints were compared between treatments in a similar
manner to the primary endpoint using a two-sided paired
t-test or Wilcoxon paired signed rank test.
Pharmacokinetics variables were estimated using non-
compartmental methods based on the PK population,
which comprised all treated subjects with completed PK
profiles on each end of treatment (EOT) study visit dur-
ing Periods 1 and 2. The effect of S. boulardii on miglu-
stat pharmacokinetics at the end of Period 1 versus
Period 2 was assessed by comparing individual and
mean plasma miglustat concentration–time profiles
and AUCτ, Cmax, and Tmax.
Results
Subjects and treatment
Subject demographics in the all-treated population are
summarized in Table 1, and subject disposition is
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screened and enrolled (the all-randomized set that
equals the all-treated set), and 21 were randomized
to each treatment sequence (i.e., miglustat + S. boulardii
then miglustat + placebo [n = 21], and miglustat + placebo
then miglustat + S. boulardii [n = 21]). Thirty-seven sub-
jects (88 %) completed the study, and there were 34 (81 %)
evaluable subjects in each of the treatment periods
(i.e., N = 34 for the PP population). Eight subjects
(19 %) were excluded from the all-treated set due to
premature discontinuation in treatment Period 1 (n = 5) or
due to dosing compliance rate <80 % (n = 3).
Subjects were well matched across both treatment
sequence groups in terms of age, gender and BMI, and
subject characteristics were similar between the all-
treated and PP sets. Overall, mean rates of compliance
with study treatment throughout the study periods and
treatments were >90 % of all subjects.
Primary endpoint
The total number of diarrhea days was not normally dis-
tributed (Fig. 3), as confirmed based on statistical valid-
ity checking based on Shapiro-Wilk (p = 0.0001) and
Anderson-Darling (p = 0.0050) criteria. Overall, the total
number of diarrhea days defined as per the primary
study endpoint was low; approximately 60 % of subjects
did not experience diarrhea during either treatment
period.Fig. 2 Subject disposition. *All-treated set, N = 42; PP set, N = 34. Five patien
rate <80%The overall mean number of diarrhea days was <1.5 days
for both treatment sequences and across both treatment
periods. The mean ± SD number of diarrhea days was
lower with miglustat + S. boulardii (0.8 ± 2.4 days; range
0–13) than with miglustat + placebo (1.3 ± 2.4 days;
range 0–8), but the paired treatment difference in the
overall PP analysis (−0.5 ± 2.4 days) was not statistically
significant (p = 0.159; Wilcoxon paired signed rank test)
(Table 2). Sensitivity analysis based on the frequency of
diarrhea days in the all-treated set yielded similar findings
(p = 0.1631; miglustat + S. boulardii versus miglustat +
placebo based on two-sided paired t-test).
A very high number of diarrhea days (n = 13) was
observed in one female subject who was randomized
to receive miglustat + placebo followed by miglustat +
S. boulardii. This subject was considered as an outlier
due to her recorded symptoms. She had: 1) WHO-
defined diarrhea of unknown cause during the initial 2
run-in days with S. boulardii before miglustat initiation;
2) a disproportionately high number of diarrhea days
compared with other patients; 3) inconsistencies in her
diary entries regarding diarrhea compared with diarrhea
judged according to the primary endpoint, which led to
contradictory quantitative and qualitative assessments of
the number of diarrhea days. An exploratory post hoc pri-
mary analysis was therefore performed that excluded this
outlier subject. Based on the primary endpoint this
post hoc analysis identified a significantly lower totalts discontinued prematurely and three subjects had a compliance
Fig. 3 Total number of diarrhea days (PP set). aOutlying subject
Table 3 Most frequently reported subject-reported outcomes*
of GI events (all-treated set)
Miglustat + S. boulardii Miglustat + placebo
(n = 40)† (n = 39)‡
Flatulence
0 (no event) 13 (33) 12 (31)
1 (mild) 8 (20) 13 (33)
2 (moderate) 11 (28) 6 (15)
3 (severe) 3 (8) 6 (15)
4 (very severe) 4 (10) 2 (5)
Bloating
0 (no event) 17 (43) 14 (36)
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(0.5 ± 1.2 days; range 0–5) versus miglustat + placebo
(1.2 ± 2.3 days; range 0–8), providing a paired treat-
ment difference of −0.7 ± 1.9 days (p < 0.05; Wilcoxon
paired signed rank test).
Secondary and exploratory endpoint analyses
Secondary efficacy analysis showed that the mean num-
ber of consecutive diarrhea days (defined as ≥3 loose
stools meeting a BSS score of 6 or 7 within consecutive
24-h periods) was generally low. The mean (SD) num-
bers of consecutive diarrhea days were 0.5 (1.48) days
with miglustat + S. boulardii and 0.9 (1.58) days with
miglustat + placebo (p = 0.2189 based on Wilcoxon
paired signed rank test for miglustat + S. boulardii versus
miglustat + placebo).
Abdominal bloating and flatulence (mostly mild or
moderate) were the most frequent GI events recorded in
subject diaries; diarrhea was the next most frequent
(Table 3). Most subjects recorded interference scores of
0 (not at all) and 1 (a little bit) based on PRO-CTCAE










(n = 34) (n = 34) (n = 34)
Mean (SD) 0.8 (2.4) 1.3 (2.4) −0.5 (2.4) 0.159*†
Range (min, max) 0, 13 0, 8 −7, 8 –
95 % CI of mean 0, 1.67 0.46, 2.13 −1.31, 0.37 –
Median 0 0 0 –
Q1, Q3 (0, 0) (0, 1) (−1, 0) –
95 % CI of median 0, 0 0, 1.00 0, 0 –
*Based on paired t test; †p = 0.042 based on Wilcoxon paired signed rank test after
one outlying subject was excluded during the post-hoc sensitivity analysisOverall, the mean (SD) BSS for Day 1 of the study was 3.7
(1.2) for the miglustat + S. boulardii treatment group and 3.6
(1.1) for the miglustat + placebo treatment group, but by
Day 16 of treatment period 1 the mean (SD) BSS was 4.3
(0.7) and 5.3 (1.0) in these treatment groups, respectively.
There were no premature discontinuations related to GI
events. Similar and low proportions of subjects (6–17 %)1 (mild) 9 (23) 10 (26)
2 (moderate) 5 (13) 11 (28)
3 (severe) 7 (18) 4 (10)
4 (very severe) 1 (3) 0 (0)
Diarrhea
0 (no event) 25 (63) 22 (56)
1 (mild) 7 (18) 7 (18)
2 (moderate) 4 (10) 6 (15)
3 (severe) 3 (8) 3 (8)
4 (very severe) 0 (0) 1 (3)
*Only the three most frequently reported GI events are included
†Miglustat + S. boulardii n = 40 (21 in Period 1 + 19 in Period 2);
‡Miglustat + placebo n = 39 (21 in Period 1 + 18 in Period 2)
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treatment sequences, with no notable difference be-
tween miglustat + S. boulardii and miglustat + placebo.
In an exploratory subgroup analysis of 12 subjects with
diarrhea days while on miglustat + placebo, the mean (SD)
number of diarrhea days during treatment was greater
with miglustat + placebo (3.7 [2.8] days) than with
miglustat + S. boulardii (2.1 [3.9] days): paired mean (SD)
treatment difference −1.6 (3.9) days (p = 0.0635 based on
Wilcoxon paired signed rank test).
Safety
Overall, treatment-emergent AEs were recorded in 30
(75 %) subjects during miglustat + S. boulardii treatment
and in 33 (85 %) subjects during miglustat + placebo treat-
ment. Most AEs affected the GI system, and were mild or
moderate. The incidence of the GI AEs also appeared to be
slightly higher with miglustat + placebo (82 %) than with
miglustat + S. boulardii (73 %). In order of decreasing inci-
dence the most common GI AEs were flatulence, abdominal
distension and diarrhea (Table 4). No subjects reported
SAEs, and no subjects discontinued therapy due to AEs. No
clinically relevant changes from baseline were observed in
hematology or blood chemistry parameters, vital signs, ECG
results or physical examination.
Pharmacokinetics
Miglustat pharmacokinetic analyses were based on measure-
ments performed in 730 blood samples from a total of 37
(88 %) evaluable subjects. There were no significant differ-
ences in miglustat Cmax, AUCτ, Tmax between the miglustat
+ S. boulardii and miglustat + placebo treatment periods.
Geometric means (coefficient of variation) were 2.5 (24.8) h
and 2.6 (25.8) h, respectively, for Tmax, 902 (40) ng/mL andTable 4 Treatment-emergent GI AEs occurring in >10 % of
subjects (all-treated set)
Category Miglustat + S. boulardii Miglustat + placebo
(n = 40)† (n = 39)‡
SOC GI disorders, n (%) 29 (73) 32 (82)
Total numbers of GI AEs 136 178
Individual AEs n (%):
Flatulence 25 (63) 26 (67)
Abdominal distention 22 (55) 24 (62)
Diarrhea 17 (43) 19 (49)
Abdominal pain 13 (33) 13 (33)
Eructation 11 (28) 13 (33)
Dyspepsia 10 (25) 13 (33)
Abdominal discomfort 22 (55) 13 (33)
Nausea 5 (13) 12 (31)
GI gastrointestinal, SOC system, organ, class
†Miglustat + S. boulardii n = 40 (21 in Period 1 + 19 in Period 2);
‡Miglustat + placebo n = 39 (21 in Period 1 + 18 in Period 2)825 (43) ng/mL, respectively, for Cmax, and 5184 (43) h˕ng/
mL and 4727 (47) h˕ng/mL, respectively, for AUCτ.
Discussion and conclusions
Clinical studies have demonstrated that miglustat is a
useful oral therapeutic option for the treatment of GD1
patients unable or unwilling to undergo intravenous
ERT, and is the only disease-specific therapy for children
and adults with NP-C [2]. The effective control of GI
disturbances during miglustat therapy is an important
clinical goal in both diseases as GI tolerability can ad-
versely affect patient quality of life and compliance with
therapy, and might hamper the effectiveness of treat-
ment in some patients.
GI disturbances during miglustat therapy vary in fre-
quency and severity according to the amount of ingested
carbohydrates and the residual ability to digest them –
patients who eat fewer or no carbohydrates while on
miglustat report fewer GI disturbances, but are more
likely to experience clinically significant weight loss due
to decreased dietary caloric intake [11, 23].
Previous data have also demonstrated that GI enzyme
substitution can reduce GI disturbances due to acquired
disaccharidase deficiency [24–26]. S. boulardii has been
shown to provide significant increases in the specific
and total activity of sucrase-isomaltase (+82 %), lactase
(+77 %), and maltase-glucoamylase (+75 %) in the intes-
tinal mucosa after 8 days of oral treatment with 250 mg
doses four times daily (total daily dose 1000 mg) [28]. In
addition, a single-center, open-label, crossover Phase I
study examined the safety, tolerability, and pharmaco-
kinetics of miglustat 1000 mg t.i.d. administered in com-
bination with sucrose, and with Baker’s yeast sucrase
(invertase) or water (control), in asymptomatic HIV-1
positive patients. The study showed that addition of
active sucrase (invertase) from Baker’s yeast extract re-
duced the incidence of loose or watery stools (data on
file at Actelion).
The rationale for the use of the yeast strain, S. boular-
dii, is to restore the capacity of the human gut to digest
sucrose. S. boulardii, given as a nutritional supplement
while miglustat is co-administered, provides an exogen-
ous sucrase (invertase) that hydrolyzes sucrose through
a different mechanism from that of human sucrase [17].
Co-administration of S. boulardii would have the advan-
tage of decreasing the need for dietary restriction or
low-carbohydrate diets, and improve GI tolerability,
comfort and compliance with miglustat therapy.
This is the first study to characterize GI AEs during
miglustat therapy, in particular diarrhea, according to
strictly defined and established clinical criteria, and
during the first 2 weeks of miglustat therapy. The
primary objective of this study, to assess whether co-
administration of S. boulardii decreases the total
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miglustat, was not met. The primary and secondary
endpoints to assess this objective did not show statis-
tically significant treatment differences between
miglustat + S. boulardii and miglustat + placebo. The
number of diarrhea days in healthy subjects receiving
miglustat + placebo was lower than expected based on
clinical trial and post-marketing experience [3, 4, 6, 12],
and limited the ability to detect a treatment effect with
S. boulardii. This lower-than-expected number of diar-
rhea days may be due to the stringent definition used for
diarrhea in the primary study endpoint as opposed to the
definition of diarrhea when reported as an AE in clinical
trials and practice. The frequency of diarrhea events re-
ported as treatment-emergent AEs in this 2-week study
(43 % with miglustat + S. boulardii and 49 % with miglu-
stat + placebo) was approximately half of that reported in
previous long-term clinical studies with miglustat (77 %
during the first 6 months of treatment or 83 % at any
time during miglustat treatment) [3, 4, 6, 12].
It is notable that further post hoc analyses of data from
the PP set, which excluded one subject who presented
with diarrhea of unknown cause prior to miglustat initi-
ation while on S. boulardii only and with highly outlying
data, gave positive results on the primary study endpoint
(based on Wilcoxon paired signed rank test). The signifi-
cantly lower number of diarrhea days observed after
exclusion of this single subject suggests that certain
patients receiving miglustat therapy may benefit from
co-administration of S. boulardii.
General safety findings were in line with the known
safety/tolerability profile for miglustat [2, 12], and there
was no indication of any new safety findings identified as
being associated with the use of miglustat in combination
with S. boulardii in this population of healthy subjects.
There were no notable treatment differences in miglustat
PK parameters between the miglustat + S. boulardii and
miglustat + placebo groups, which supports the hypothesis
that co-administration with S. boulardii does not alter the
steady-state PK of miglustat.
In terms of study limitations, while it would be prefer-
able to assess the concomitant use of miglustat with
S. boulardii in patients with approved indications (i.e.,
GD1 and NP-C), in whom the incidence of GI AEs has
been adequately verified, it should be borne in mind that
GD1 and NP-C are rare conditions. Healthy subjects
were selected for this study for practical considerations,
given the limited feasibility of patient recruitment within
these indicated orphan populations and the fact that GI
disturbances during miglustat treatment to date have
generally been similar across all populations [2, 12]. It
was therefore considered appropriate to extrapolate find-
ings in healthy subjects to those in patients with GD1 or
NP-C.In summary, the primary endpoint analysis in this
study did not demonstrate statistically significant im-
provement in the GI tolerability of miglustat co-
administered with S. boulardii. A post-hoc analysis of the
primary endpoint, which excluded a subject judged as a
clear outlier, showed a statistically significant result,
suggesting that the GI tolerability of miglustat might be
improved with the concomitant use of S. boulardii.
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